GLG News by Restylane Users for Wrinkles: Dermatologists

Galderma has bought out CollaGenex for $420 million. In July 2006, CollaGenex launched Oracea®, the first FDA-approved systemic product for rosacea. CollaGenex is also developing Col-118, a novel product for the treatment of the erythema.

Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces the entry of AS1409 into clinical trials. A phase I trial has started in patients with renal cancer and melanoma. The trial has two parts. In the first, successive cohorts of patients will receive increasing doses of AS1409....

Phosphagenics’s topical retinoic acid, aided with their proprietary drug delivery platform, has shown significant reduction in irritation scores in their pre-clinical studies for the treatment of acne.

This is Humira’s 6th indication, and 2nd within the last 2 months.  It was approved for moderate to severe chronic plaque psoriasis in Jan 2008. 

Marc Engelman, a former drug representative for Enbrel, claimed that Amgen required salespeople to gain access to patient medical information in doctors' offices.  The alleged intent was to market the drug directly to patients, several of whom may not have needed the medication.

Th17 cells were found to be three times greater in the skin in psoriasis patients compared that of healthy people.

Their findings (directly from the website)- Investigators reported findings from PHOENIX 1 that showed at week 12, after two doses, 67 percent of patients receiving 45 mg ustekinumab and 66 percent of patients receiving 90 mg ustekinumab achieved PASI 75 (compared with 3 percent of patients receiving...

Their findings (directly from the website)- During the 48-week study, the percentage of patients achieving 75 percent or greater disease improvement from baseline, as measured by the standard Psoriasis Area and Severity Index (PASI 75), was used to evaluate the efficacy of ENBREL in patients between...

HUMIRA has been in the dermatology arena ever since it was approved for psoriatic arthritis.  Dermatologists could prescribe HUMIRA for their psoriatic patients who also had a component of arthritis.  However, 60-90% of psoriatic patients have psoriatic arthritis.  ...

ABT-874 was studied in a phase 2, 12-week, multicenter, randomized, double-blind, placebo-controlled trial for Moderate to Severe Chronic Plaque Psoriasis.  180 Patients were randomized to receive 1 of 6 treatments: one 200-mg dose at week 0; 100 mg every other week for 12 weeks; 200 mg weekly...